Nabiqasim Industries (Pvt) Ltd.,
Private pharmaceutical manufacturer · Karachi · Pakistan
Pakistan-based pharmaceutical manufacturer producing branded generic formulations with domestic and international operations.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Nabiqasim Industries (Pvt.) Ltd.
- Company type
- Private pharmaceutical manufacturer
- Address
- 5th Floor, Commerce Centre, Hasrat Mohani Road, Karachi, Pakistan
- Website
- nabiqasim.com ↗
- Phone
- +92 21 111 742 762
- info@nabiqasim.com
- Official contact
- Contact page ↗
- Official company profile ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Hypovir | Aciclovir | 500 mg | IV injection | 1's | 101083 | PKR 1,200.28 | PKR 1,200.28/vial/unit | No comparator |
| Hypovir | Aciclovir | 250 mg | Injection | 1's | 108661 | PKR 534.17 | PKR 534.17/vial/unit | 11% below median |
| Hypovir | Aciclovir | 250 mg | Injection | 1's | 108961 | PKR 550.94 | PKR 550.94/vial/unit | 7% below median |
| Inzivir | Oseltamivir | 75 mg | Capsule | 10's | 101329 | PKR 1,204.29 | PKR 120.43/capsule | Near median |
| Lamozid | Lamivudine + Zidovudine | 150 mg + 300 mg | Tablet | 30's | 039709 | PKR 3,176.37 | PKR 105.88/tablet | Near median |
| Lamozid | Lamivudine + Zidovudine | 150 mg + 300 mg | Tablet | 10's | 039709 | PKR 1,058.79 | PKR 105.88/tablet | Near median |
| Lamvira | Lamivudine | 150 mg | Tablet | 30's | 042479 | PKR 2,174.44 | PKR 72.48/tablet | 8% above median |
| Lamvira | Lamivudine | 150 mg | Tablet | 10's | 042479 | PKR 830.94 | PKR 83.09/tablet | 35% above median |
| Lamvira | Lamivudine | 300 mg | Tablet | 30's | 042480 | PKR 3,950.88 | PKR 131.70/tablet | Near median |
| Lamvira | Lamivudine | 300 mg | Tablet | 10's | 042480 | PKR 1,378.44 | PKR 137.84/tablet | Near median |
| Linox | Linezolid | 600 mg | Tablet | 12's | 081180 | PKR 5,204.59 | PKR 433.72/tablet | 10% above median |
| Linox | Linezolid | 100 mg/5 mL | Dry suspension | 60ml | 081563 | PKR 712.67 | PKR 11.88/mL | 10% above median |
| Linox | Linezolid | 100 mg/5 mL | Dry suspension | 120ml | 081563 | PKR 1,354.09 | PKR 11.28/mL | Near median |
| Linox | Linezolid | 400 mg | Tablet | 12's | 089044 | PKR 2,912.33 | PKR 242.69/tablet | 5% above median |
| Livent | Entecavir | 0.5 mg | Tablet | 30s | 108959 | PKR 6,960.22 | PKR 232.01/tablet | 35% below median |
| Livent | Entecavir | 0.5 mg | Tablet | 20s | 108959 | PKR 4,790.36 | PKR 239.52/tablet | 33% below median |
| Livent | Entecavir | 1 mg | Tablet | 30s | 108960 | PKR 11,599.43 | PKR 386.65/tablet | 35% below median |
| Livent | Entecavir | 1 mg | Tablet | 20s | 108960 | PKR 7,985.82 | PKR 399.29/tablet | 33% below median |
| Maxithro | Erythromycin | 200 mg/5 mL | Oral suspension | 60ml | 045214 | PKR 62.55 | PKR 1.04/mL | No comparator |
| Meflox | Moxifloxacin | 400 mg | Tablet | 5's | 055621 | PKR 989.02 | PKR 197.80/tablet | 7% above median |
| Miniquine | Chloroquine | 81 mg/5 mL | Syrup | 60ml | 002731 | PKR 31.63 | PKR 0.53/mL | 16% below median |
| Miniquine | Chloroquine | 81 mg/5 mL | Syrup | 30ml | 002731 | PKR 25.17 | PKR 0.84/mL | 46% above median |
| Miniquine | Chloroquine | 250 mg | Tablet | 50's | 101328 | PKR 619.81 | PKR 12.40/tablet | 703% above median |
| Mycoderm | Terbinafine | 1 % | Cream | 10gm | 085592 | PKR 294.42 | PKR 29.44/g | Near median |
| Mycoderm | Terbinafine | 1% | Cream | 15gm | 085592 | PKR 404.76 | PKR 26.98/g | Near median |
| Mycoderm | Terbinafine | 1 % | Solution | 15g | 135206 | PKR 223.00 | PKR 14.87/g | No comparator |
| Mycoderm Topical | Terbinafine | 1 % | Spray | 30ml | 120032 | PKR 837.76 | PKR 27.93/mL | No comparator |
| Myzocort | Miconazole + Hydrocortisone | 20 mg/g + 10 mg/g | Cream | 10gm | 034466 | PKR 100.95 | PKR 10.10/g | No comparator |
| Myzoderm | Miconazole | 20 mg | Cream | 20gm | 034467 | PKR 116.49 | PKR 5.82/g | 24% below median |
| Myzoderm | Miconazole | 20 mg | Cream | 10gm | 034467 | PKR 58.24 | PKR 5.82/g | 24% below median |
| Myzogel | Miconazole | 20 mg | Gel | 20gm | 034465 | PKR 168.90 | PKR 8.45/g | Near median |
| Myzogel | Miconazole | 20 mg | Gel | 10gm | 034465 | PKR 83.48 | PKR 8.35/g | Near median |
| Myzogel | Miconazole | 20 mg | Gel | 5gm | 034465 | PKR 50.49 | PKR 10.10/g | 20% above median |
| Myzovag Vaginal | Miconazole | 20 mg/g | Vaginal cream | 20gm | 034468 | PKR 116.49 | PKR 5.82/g | 10% below median |
| Myzovag Vaginal | Miconazole | 20 mg | Vaginal cream | 40gm | 034468 | PKR 221.31 | PKR 5.53/g | No comparator |
| Navospet | Chlorhexidine gluconate | 7.1 % | Gel | 10g | 107734 | PKR 84.56 | PKR 8.46/g | Near median |
| Nixmetic | Mebendazole | 500 mg | Tablet | 12’s | 107702 | PKR 448.70 | PKR 37.39/tablet | 12% above median |
| Nogotex | Colistimethate sodium | 1 MIU | Lyophilized powder for injection | 1’s | 107445 | PKR 2,761.25 | PKR 2,761.25/vial/unit | No comparator |
| Nogotex | Colistimethate sodium | 2 MIU | Injection | 1s | 110206 | PKR 2,000.07 | PKR 2,000.07/vial/unit | Near median |
| Nogotex | Colistimethate sodium | 3 MIU | IV injection | 1s | 110207 | PKR 3,000.68 | PKR 3,000.68/vial/unit | No comparator |
| Nogotex | Colistimethate sodium | 4.5 MIU (≈150 mg colistin base activity) | Injection | 1's | 116202 | PKR 4,501.60 | PKR 4,501.60/vial/unit | 13% above median |
| Nogotex | Colistimethate sodium | 4.5 MIU | Injection | 1's | 116202 | PKR 4,501.60 | PKR 4,501.60/vial/unit | Near median |
| Ophthaflox | Ciprofloxacin | 0.3 % | Drops | 5ml | 039706 | PKR 196.22 | PKR 39.24/mL | No comparator |
| Penrrem | Meropenem | 1 g | Powder for injection | 1's | 123174 | PKR 4,130.52 | PKR 4,130.52/vial/unit | 5% above median |
| Penrrem, Dry | Meropenem | 500 mg | Injection | 1's | 123173 | PKR 2,209.83 | PKR 2,209.83/vial/unit | 6% above median |
| Piquin | Dihydroartemisinin + Piperaquine | 40 mg + 320 mg | Capsule | 8's | 075866 | PKR 758.00 | PKR 94.75/capsule | Near median |
| Racona | Itraconazole | 100 mg | Capsule | 4's | 108656 | PKR 517.74 | PKR 129.44/capsule | 11% below median |
| Rivab | Ribavirin | 200 mg | Capsule | 10's | 083984 | PKR 475.63 | PKR 47.56/capsule | Near median |
| Rivab | Ribavirin | 400 mg | Tablet | 10's | 095985 | PKR 174.74 | PKR 17.47/tablet | Near median |
| Romycin | Azithromycin | 250 mg | Capsule | 6's | 024331 | PKR 372.74 | PKR 62.12/capsule | 26% above median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.